

**Request under Freedom of Information Act 2000**

Thank you for your request for information which we received on Tuesday 2<sup>nd</sup> April 2024. I am pleased to confirm the following.

**Q1. How many patients were treated in March 2024 (or latest available month) by the Dermatology department with the following drugs:**

Abrocitinib (Cibinqo)	0 patients
Baricitinib (Olmiant)	0 patients
Dupilumab (Dupixent)	23 patients
Lebrikizumab (Ebglyss)	0 patients
Omalizumab (Xolair)	0 patients
Tralokinumab (Adtralza)	0 patients
Upadacitinib (Rinvoq)	1 patient

**Q2. How many patients were treated in March 2024 (or latest available month) by the Respiratory Medicine departments with the following drugs:**

Benralizumab (Fasenra)	0 patients
Dupilumab (Dupixent)	0 patients
Mepolizumab (Nucala)	0 patients
Omalizumab (Xolair)	0 patients
Reslizumab (Cinqaero)	0 patients
Tezepelumab (Tezspire)	0 patients

Please be advised that this information is provided in accordance with the Freedom of Information Act 2000 and is for your personal use. Any re-use of this information will be subject to copyright and the Re-Use of Public Sector Information Regulations (1st July 05) and authorisation from Milton Keynes Hospital NHS Foundation Trust will be required. In the event of any re-use, the information must be reproduced accurately and not used in a misleading manner.

If you are unhappy with the information received in response to this request, please address your complaint to the Patient Affairs Office at Milton Keynes Hospital NHS Foundation Trust, Standing Way, Eaglestone, Milton Keynes MK6 5LD. If, after exhausting our internal process, you are still unhappy with the information received, you may write to the Information Commissioner's Office, Wycliffe House, Water Lane, Wilmslow, Cheshire SK9 5AF.

If you need any further assistance, please do not hesitate to contact us at the address above.

Yours sincerely

Freedom of Information Co-ordinator  
For and on behalf of Milton Keynes Hospital NHS Foundation Trust

Any re-use of this information will be subject to the  
'Re-use of Public Sector Information Regulations' and best practice.